Amelioration of Glucolipotoxicity-Induced Endoplasmic Reticulum Stress by a "Chemical Chaperone" in Human THP-1 Monocytes. (10th April 2012)

• Record Type: Journal Article
• Authors: Lenin, Raji; Maria, Mariawilliam Sneha; Agrawal, Madhur; Balasubramanyam, Jayashree; Mohan, Viswanathan; Balasubramanyam, Muthuswamy
• Other Names: Sampathkumar Rangasamy Academic Editor.
• Is Part Of: Experimental diabetes research. Volume 2012(2012)
• Publication Date: 2012-04-10
• Subjects: Diabetes -- Research -- Periodicals; Diabetes -- Research; Periodicals; 616.462
• DOI: 10.1155/2012/356487
• Languages: English
• ISSNs: 1687-5214

Abstract

Abstract : Chronic ER stress is emerging as a trigger that imbalances a number of systemic and arterial-wall factors and promote atherosclerosis. Macrophage apoptosis within advanced atherosclerotic lesions is also known to increase the risk of atherothrombotic disease. We hypothesize that glucolipotoxicity might mediate monocyte activation and apoptosis through ER stress. Therefore, the aims of this study are (a) to investigate whether glucolipotoxicity could impose ER stress and apoptosis in THP-1 human monocytes and (b) to investigate whether 4-Phenyl butyric acid (PBA), a chemical chaperone could resist the glucolipotoxicity-induced ER stress and apoptosis. Cells subjected to either glucolipotoxicity or tunicamycin exhibited increased ROS generation, gene and protein (PERK, GRP-78, IRE1 α, and CHOP) expression of ER stress markers. In addition, these cells showed increased TRPC-6 channel expression and apoptosis as revealed by DNA damage and increased caspase-3 activity. While glucolipotoxicity/tunicamycin increased oxidative stress, ER stress, mRNA expression of TRPC-6, and programmed the THP-1 monocytes towards apoptosis, all these molecular perturbations were resisted by PBA. Since ER stress is one of the underlying causes of monocyte dysfunction in diabetes and atherosclerosis, our study emphasize that chemical chaperones such as PBA could alleviate ER stress and have potential to become novel therapeutics.